Your browser doesn't support javascript.
loading
Risk factors for pulmonary tuberculosis recurrence, relapse and reinfection: a systematic review and meta-analysis.
Vega, Victor; Cabrera-Sanchez, Javier; Rodríguez, Sharon; Verdonck, Kristien; Seas, Carlos; Otero, Larissa; Van der Stuyft, Patrick.
Afiliação
  • Vega V; Universidad Peruana Cayetano Heredia Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru victor.vega.z@upch.pe.
  • Cabrera-Sanchez J; Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Rodríguez S; Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Verdonck K; Department of Public Health, Institute of Tropical Medicine, Antwerpen, Belgium.
  • Seas C; Universidad Peruana Cayetano Heredia Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru.
  • Otero L; Facultad de Medicina, Universidad Peruana Cayetano Heredia, Lima, Peru.
  • Van der Stuyft P; Departamento de Enfermedades Infecciosas, Tropicales y Dermatológicas, Hospital Cayetano Heredia, Lima, Peru.
BMJ Open Respir Res ; 11(1)2024 Mar 13.
Article em En | MEDLINE | ID: mdl-38479821
ABSTRACT

BACKGROUND:

The rate of pulmonary tuberculosis (TB) recurrence is substantial. Identifying risk factors can support the development of prevention strategies.

METHODS:

We retrieved studies published between 1 January 1980 and 31 December 2022 that assessed factors associated with undifferentiated TB recurrence, relapse or reinfection. For factors reported in at least four studies, we performed random-effects meta-analysis to estimate a pooled relative risk (RR). We assessed heterogeneity, risk of publication bias and certainty of evidence.

RESULTS:

We included 85 studies in the review; 81 documented risk factors for undifferentiated recurrence, 17 for relapse and 10 for reinfection. The scope for meta-analyses was limited given the wide variety of factors studied, inconsistency in control for confounding and the fact that only few studies employed molecular genotyping. Factors that significantly contributed to moderately or strongly increased pooled risk and scored at least moderate certainty of evidence were for undifferentiated recurrence, multidrug resistance (MDR) (RR 3.49; 95% CI 1.86 to 6.53) and fixed-dose combination TB drugs (RR 2.29; 95% CI 1.10 to 4.75) in the previous episode; for relapse, none; and for reinfection, HIV infection (RR 4.65; 95% CI 1.71 to 12.65). Low adherence to treatment increased the pooled risk of recurrence 3.3-fold (95% CI 2.37 to 4.62), but the certainty of evidence was weak.

CONCLUSION:

This review emphasises the need for standardising methods for TB recurrence research. Actively pursuing MDR prevention, facilitating retention in treatment and providing integrated care for patients with HIV could curb recurrence rates. The use of fixed-dose combinations of TB drugs under field conditions merits further attention. PROSPERO REGISTRATION NUMBER CRD42018077867.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose Pulmonar / Infecções por HIV Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose Pulmonar / Infecções por HIV Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article